ALMR

Alamar Biosciences Inc

25.28

Oct 16 • 3:59 PM ET -2.14 (-7.80%)

25.28

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Medical Devices USA Small NASD

Peers: INMD IRTC GKOS BSX EW MDT TFX BAX BDX RMD

| Held by: ARKG VTI IWM VXF VTWO IWO SCHA IWN ONEQ VTWG

Scroll to Statements

Index	RUT
Market Cap	1.75B
Enterprise Value	1.56B
Income	-
Sales	-
Book/sh	4.51
Cash/sh	3.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	222
IPO	Apr 17, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.61
P/C	7.02
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.23
Current Ratio	11.85
Debt/Eq	0.16
LT Debt/Eq	0.16
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-0.59
EPS next Q	-0.20
EPS this Y	-455.49%
EPS next Y	49.13%
EPS next 5Y	-10.86%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Nov 03 AMC
EPS/Sales Surpr.	28.55% 13.69%

Insider Own	48.36%
Insider Trans	1.42%
Inst Own	24.83%
Inst Trans	65.55%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-16.81%
SMA50	-18.57%
SMA200	-5.05%
Trades

Shs Outstand	69.39M
Shs Float	35.83M
Short Float	7.85%
Short Ratio	6.12
Short Interest	2.81M
52W High	39.61 -36.18%
52W Low	18.84 34.15%
Volatility	10.39% 9.96%
ATR (14)	2.78
RSI (14)	40.87
Beta	-
Rel Volume	0.99
Avg Volume	459.14K
Volume	456,294

Perf Week	0.04%
Perf Month	-21.02%
Perf Quarter	5.69%
Perf Half Y	14.91%
Perf YTD	11.86%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.40
Target Price	35.40
Prev Close	27.42
Price	25.28
Change %	-7.80%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	TD Cowen	Buy	$30
May-12-26	Initiated	Stifel	Buy	$28
May-12-26	Initiated	Leerink Partners	Outperform	$35
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	BofA Securities	Neutral	$27

Oct-08-26 04:05PM	Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire) -6.70%
Oct-05-26 04:05PM	Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team (GlobeNewswire) +10.97% -15.39%
Sep-24-26 06:51PM	Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment (GlobeNewswire)
Sep-01-26 04:05PM	Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-26 01:02AM	Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... (GuruFocus.com) +30.65%
04:38PM	Loading…
Aug-10-26 04:38PM	Alamar: Q2 Earnings Snapshot (Associated Press)
04:05PM	Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance (GlobeNewswire)
04:03PM	Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures (GlobeNewswire)
Aug-05-26 08:05AM	Attovia adds to biotech IPO momentum with $289M offering (BioPharma Dive)
Jul-28-26 04:12PM	Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome (GlobeNewswire)
Jul-15-26 07:34AM	Braveheart, Attovia join next wave of biotech IPOs (BioPharma Dive)
Jul-14-26 04:05PM	Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 (GlobeNewswire)
Jul-13-26 04:50PM	Alamar Hits A High Note On Alzheimer's Buzz (Trefis)
02:30AM	Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases (GlobeNewswire)
Jul-10-26 06:11AM	Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling (GlobeNewswire) +7.33%
09:12AM	Loading…
Jul-07-26 09:12AM	Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research (GlobeNewswire)
Jul-01-26 09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
May-12-26 09:56AM	Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls (The Fly)
May-08-26 08:00AM	Alamar Biosciences Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:05PM	Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference (GlobeNewswire)
Apr-19-26 10:41PM	Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ (PR Newswire)

Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.

Co-FounderDr. Yuling Luo Ph.D.

Co-FounderDr. Shiping Chen Ph.D.

Chief Financial OfficerMr. Justin J. McAnear

PresidentMr. Timothy Ogden White J.D.

Co-FounderMs. Yiyuan Yin Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Qiming Venture Partners VIII-H	Affiliate	Oct 14 '26	Proposed Sale	23.52	435,468	10,242,000		Oct 14 08:33 PM
Qiming Venture Partners VIII I	Affiliate	Oct 14 '26	Proposed Sale	23.52	363,729	8,555,000		Oct 14 08:23 PM
Qiming Venture Partners VI, L.	Affiliate	Oct 14 '26	Proposed Sale	23.52	1,558,858	36,664,000		Oct 14 08:20 PM
Qiming Managing Directors Fund	Affiliate	Oct 14 '26	Proposed Sale	23.53	41,945	987,000		Oct 14 08:15 PM
Illumina Innovation Fund II GP	10% Owner	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:45 PM
Naclerio Nicholas	Director	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMR

Alamar Biosciences Inc

Upgrade your Finviz experience